Ipsen SA
PAR:IPN

Watchlist Manager
Ipsen SA Logo
Ipsen SA
PAR:IPN
Watchlist
Price: 108.6 EUR -0.46% Market Closed
Market Cap: 9.1B EUR
Have any thoughts about
Ipsen SA?
Write Note

Gross Margin
Ipsen SA

82%
Current
83%
Average
48.4%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
82%
=
Gross Profit
2.8B
/
Revenue
3.4B

Gross Margin Across Competitors

Country Company Market Cap Gross
Margin
FR
Ipsen SA
PAR:IPN
9B EUR
82%
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY
-3%
US
Eli Lilly and Co
NYSE:LLY
755.8B USD
81%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
56%
DK
Novo Nordisk A/S
CSE:NOVO B
2.7T DKK
85%
US
Johnson & Johnson
NYSE:JNJ
351.1B USD
69%
US
Merck & Co Inc
NYSE:MRK
251.8B USD
77%
CH
Roche Holding AG
SIX:ROG
200.1B CHF
73%
UK
AstraZeneca PLC
LSE:AZN
161.8B GBP
82%
CH
Novartis AG
SIX:NOVN
171.5B CHF
75%
US
Pfizer Inc
NYSE:PFE
151.5B USD
71%
Country FR
Market Cap 9B EUR
Gross Margin
82%
Country JP
Market Cap 776 550.9T JPY
Gross Margin
-3%
Country US
Market Cap 755.8B USD
Gross Margin
81%
Country UK
Market Cap 440.4B GBP
Gross Margin
56%
Country DK
Market Cap 2.7T DKK
Gross Margin
85%
Country US
Market Cap 351.1B USD
Gross Margin
69%
Country US
Market Cap 251.8B USD
Gross Margin
77%
Country CH
Market Cap 200.1B CHF
Gross Margin
73%
Country UK
Market Cap 161.8B GBP
Gross Margin
82%
Country CH
Market Cap 171.5B CHF
Gross Margin
75%
Country US
Market Cap 151.5B USD
Gross Margin
71%
No Stocks Found

Ipsen SA
Glance View

Market Cap
9B EUR
Industry
Pharmaceuticals

Ipsen SA, headquartered in France, is a prominent player in the global biopharmaceutical realm, weaving its story through its commitment to innovation and specialization. Founded in 1929, this family-owned company has evolved significantly, utilizing a diverse mix of scientific research and strategic acquisitions to fuel its growth. Ipsen operates through three principal business segments: Specialty Care, Consumer Healthcare, and Research & Development. Specialty Care, which includes oncology, neuroscience, and rare diseases, is the heart of Ipsen's portfolio, contributing the lion's share of its revenue. The company has honed its focus on developing targeted therapies for complex conditions, leveraging its adeptness in peptide and toxin research. Its success lies in the balance of nurturing homegrown research while acquiring promising biotech firms and novel therapies to expand its offerings and market reach. Beyond its scientific and research prowess, Ipsen's financial robustness stems from a well-orchestrated strategy that intertwines its business operations. The company generates substantial revenue by not only launching innovative products but also through strategic partnerships and licensing agreements that broaden its geographic footprint. Ipsen’s Consumer Healthcare segment complements its operations by delivering over-the-counter products that maintain a steady cash flow, though on a smaller scale compared to Specialty Care. Meanwhile, its Research & Development arm remains the crucible for future growth, as Ipsen invests significantly in pioneering future therapies that align with its core areas of expertise. Through this strategic tapestry, Ipsen has positioned itself as a dynamic entity in the biopharmaceutical industry, consistently striving to deliver value while advancing the frontiers of medicine.

IPN Intrinsic Value
151.09 EUR
Undervaluation 28%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
82%
=
Gross Profit
2.8B
/
Revenue
3.4B
What is the Gross Margin of Ipsen SA?

Based on Ipsen SA's most recent financial statements, the company has Gross Margin of 82%.